Related Experiment Video

Updated: Sep 20, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Interferon-beta treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity

Karin Hellman1, Ewa Roos, Anna Osterlund

  • 1Division of Clinical Pharmacology, Department of Laboratory Medicine, NEUROTEC, Karolinska Institutet at Huddinge University Hospital, S-141 86 Huddinge, Sweden.

British Journal of Clinical Pharmacology
|August 16, 2003
PubMed
Abstract

Insights

Interferon-beta treatment does not alter the activity of drug-metabolizing enzymes CYP2C19 or CYP2D6 in multiple sclerosis patients. This indicates safe co-administration of their substrates without dose adjustments.

Area of Science:

  • Pharmacogenetics
  • Neuroimmunology
  • Drug Metabolism

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Interferon-beta (IFN-beta) is a common disease-modifying therapy for MS.
  • Understanding drug-drug interactions is crucial for managing MS patients on multiple medications.

Purpose of the Study:

  • To investigate the impact of interferon-beta (IFN-beta) treatment on the activity of key drug-metabolizing enzymes, specifically CYP2C19 and CYP2D6.
  • To assess potential alterations in metabolic ratios for probe drugs used to determine CYP2C19 and CYP2D6 activity before and during IFN-beta therapy in MS patients.

Main Methods:

  • Assessed CYP2C19 and CYP2D6 activity using mephenytoin and debrisoquine probe drugs, respectively.
  • Measured urinary metabolic ratios (MR) for mephenytoin (S/R) and debrisoquine (debrisoquine/hydroxy-debrisoquine) in 10 MS patients.
  • Performed genotyping for common CYP2C19 and CYP2D6 genetic variants (CYP2C19*2, *3; CYP2D6*3, *4, *5).

Main Results:

  • No significant differences were observed in the (S)/(R) mephenytoin ratio or debrisoquine MR before and during IFN-beta treatment in extensive metabolizers (EM).
  • Analysis showed no significant changes in enzyme activity regardless of the specific IFN-beta formulation used.
  • Genotyping data were collected but not explicitly detailed in the results summary regarding their direct impact on the observed metabolic ratios.

Conclusions:

  • Interferon-beta treatment does not appear to affect the metabolic activity of CYP2C19 or CYP2D6 in patients with multiple sclerosis.
  • The findings suggest that substrates of CYP2C19 and CYP2D6 can be safely administered to MS patients undergoing IFN-beta therapy.
  • No dose adjustments are likely necessary for medications metabolized by these enzymes when co-administered with IFN-beta.

More Related Videos

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...